An Injectable Method for Posterior Lateral Spine Fusion
Annual rept. 1 Sep 2012-31 Aug 2013
BAYLOR COLL OF MEDICINE HOUSTON TX
Pagination or Media Count:
The central hypothesis of this application is that posterolateral spine fusion can be successfully achieved with a novel and simple minimally invasive percutaneous injection. We propose that this can be done by injection of AdBMP2 transduced human fibroblasts possessing an icasp9M that have been micro-encapsulated with osteoclast degradable hydrogel into the desired fusion site. During this first year, we have initiated the identification of the phenotype of the monocyte-like cells that appear to be capable of bone degradation. We have demonstrated in MSCs, which have a stably integrated icasp9M, can be rapidly induced to undergo apoptosis, after delivery of a chemical inducer of dimerization CID after encapsulation in PEG hydrogel. The next step is to start in vivo testing of this system. Additionally we have developed the methodology to non-invasively locate the hydrogel microsphere placement, optically, with respect to the newly forming bone. This has lead to a publication. We have also initiated studies to fuse the spine using our cell based gene therapy system encapsulated in the PEG hydrogel microspheres, in both mouse and rat. We will continue to complete these studies in the upcoming year.
- Anatomy and Physiology
- Medicine and Medical Research